Tesamorelin reconstitution calculator
approved as Egrifta®
Tesamorelin is a stabilized GHRH analog and a genuine FDA-approved drug - the strongest evidence base of any GH-axis peptide, including controlled data on visceral adipose tissue reduction. The gray zone is indication, not molecule: approved for HIV lipodystrophy, marketed by clinics for everyone else's belly fat.
Enter vial size, water volume, and the dose your provider gave you.
This tool converts the numbers you enter (dose ÷ concentration = volume). It never suggests a dose. The FDA has documented hospitalizations caused by mg / ml / unit conversion errors with vial-and-syringe products - if the readout surprises you, stop and verify with your prescriber or pharmacist.
Questions people actually search
How is Egrifta (tesamorelin) dosed on-label?
The approved regimen is 2 mg (original) or 1.28 mg (Egrifta SV/WR formulations) once daily subcutaneously, per the label for HIV-associated lipodystrophy. Reconstitution volumes differ by formulation - always follow the product's own instructions over any calculator.
Does tesamorelin reduce belly fat in people without HIV?
Its visceral-fat data comes from HIV-lipodystrophy populations, with supportive smaller studies elsewhere (including NAFLD research). Efficacy in the general population is plausible but not what the FDA reviewed - off-label use is a prescriber judgment, not an approved claim.
Why is tesamorelin so much more expensive than sermorelin?
It's a patented, branded, currently marketed drug with pharma pricing, versus a decades-old molecule made by compounders. Clinics often position sermorelin as the budget option and tesamorelin as the evidence option - that framing is roughly honest.